Pipeline

Our novel pipeline is purposefully designed to advance LIFT BioSciences’ platform of delivering transformational, allogeneic neutrophil based therapies that meaningfully improve patient outcomes. Spanning unmodified IMANs and next-generation Engineered IMANs, our programs reflect a strategic, risk-balanced approach that validates our technology across multiple solid tumour indications. With our lead IMAN program progressing towards the clinic for a Phase 1 clinical trial in HNSCC and CSCC, and our engineered IMAN platform advancing through validation, we are building a robust pipeline to bring scalable, durable, and accessible therapies to patients in need.

​

Our IP strategy provides tailored protection for these programs. Relevant patent filings provide cover for compositions of matter, focused methods of treatment/medical uses, alone and in combinations, and also methods of manufacturing IMANs.